BioCryst Pharmaceuticals, Inc. Q3 2023 Earnings Call Transcript
Slightly above 67% of BioCryst Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding BioCryst Pharmaceuticals suggests that many traders are alarmed. BioCryst Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, BioCryst Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
BioCryst |
Operator Good morning and welcome to the BioCryst Pharmaceuticals Third Quarter 2023 Earnings Call. Operator Instructions Please note, this event is being recorded.
Read at insidermonkey.com
 |
BioCryst Pharmaceuticals Fundamental Analysis
We analyze BioCryst Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of BioCryst Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of BioCryst Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Sales
Price To Sales Comparative Analysis
BioCryst Pharmaceuticals is currently under evaluation in price to sales category among its peers. Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
BioCryst Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with BioCryst Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of BioCryst Pharmaceuticals could also be used in its relative valuation, which is a method of valuing BioCryst Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
BioCryst Pharmaceuticals Related Equities
| XFOR | X4 Pharmaceuticals | 13.85 | ||||
| AXSM | Axsome Therapeutics | 4.27 | ||||
| APLS | Apellis Pharmaceuticals | 1.42 | ||||
| BPMC | Blueprint Medicines | 1.14 | ||||
| PDSB | PDS Biotechnology | 1.03 | ||||
| DAWN | Day One | 0.16 | ||||
| IMUX | Immunic | 0.00 | ||||
| KZR | Kezar Life | 0.91 | ||||
| VKTX | Viking Therapeutics | 1.12 | ||||
| MCRB | Seres Therapeutics | 1.12 | ||||
| ATRA | Atara Biotherapeutics | 1.52 | ||||
| MDGL | Madrigal Pharmaceuticals | 1.58 | ||||
| INMB | INmune Bio | 1.77 | ||||
| BIVI | Biovie | 1.97 | ||||
| TGTX | TG Therapeutics | 2.41 | ||||
| SAVA | Cassava Sciences | 3.38 | ||||
| CGTX | Cognition Therapeutics | 6.25 | ||||
| PIRS | Pieris Pharmaceuticals | 15.69 |
Additional Tools for BioCryst Stock Analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.